Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Avastin Supply Will Come From Two Sites; BLA Coming Soon

Executive Summary

Commercial supply for Genentech's vascular endothelial growth factor inhibitor Avastin could come from two manufacturing facilities, Chief Medical Officer Susan Hellmann, MD, said during an investor conference call July 9

You may also be interested in...



Genentech To Submit Avastin sBLA For Vacaville Facility In First Half 2004

Genentech will submit an sBLA for a back-up manufacturing site for the oncologic Avastin during the first half of 2004

Genentech To Submit Avastin sBLA For Vacaville Facility In First Half 2004

Genentech will submit an sBLA for a back-up manufacturing site for the oncologic Avastin during the first half of 2004

Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing

Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich

Related Content

UsernamePublicRestriction

Register

PS042156

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel